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Abstract 
Diagnosis of Parkinson's disease (PD) is currently assessed by the clinical evaluation of 
extrapyramidal signs. The identification of specific biomarkers would be advisable, 
however most studies stop at the discovery phase, with no biomarkers reaching clinical 
exploitation. To this purpose, we developed an automated literature analysis procedure 
to retrieve all the background knowledge available in public databases. The 
bioinformatic platform allowed us to analyze more than 51000 scientific papers dealing 
with PD, containing information on 4121 proteins. Out of these, we could track back 35 
PD-related proteins as present in at least two published 2-DE maps of human plasma. 
Then, 9 different proteins (haptoglobin, transthyretin, apolipoprotein A-1, serum 
amyloid P component, apolipoprotein E, complement factor H, fibrinogen γ, thrombin, 
complement C3) split into 32 spots were identified as a potential diagnostic pattern. 
Eventually, we compared the collected literature data to experimental gels from 90 
subjects (45 PD patients, 45 non-neurodegenerative control subjects) to experimentally 
verify their potential as plasma biomarkers of PD.  
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1. Introduction 
The identification of specific biomarkers for neurodegenerative disorders is one of the 
main goal of the current clinical research. Diagnosis of the second most common 
neurological disorder, Parkinson's disease (PD), is currently assessed by the clinical 
evaluation of extrapyramidal signs, such as tremor, rigidity and bradykinesia, when the 
degeneration of dopaminergic nigral neurons has raised over 70%
 
[1],[2]. The 
identification of peripheral PD biomarkers would be critical for the differential 
diagnosis between PD and other neurodegenerative diseases that share some clinical 
features with PD. Moreover, early diagnosis remains a primary aim, needed also for the 
assessment of disease-modifying drugs [3],[4],[5]. Eventually, biomarkers of disease 
progression would allow a better patients follow-up and an objective measurement in 
clinical trials [6]. Non-motor signs frequently precede the onset of typical PD motor 
dysfunctions but they lack the specificity to be informative for the clinician; on the 
other hand, instrumental investigations (polysomnograpy or functional imaging) are 
characterized by high costs and the use of radioactive tracers. For these reasons, a 
biochemical marker to be evaluated in the periphery would be highly preferred 
[3],[4],[5].  
Several PD biomarker candidates were discovered using unbiased proteomic 
approaches [4],[7]. 2-DE is able to resolve thousands of spots simultaneously and can 
visualize protein processing and post-translational modifications [8]. For these reasons, 
it has been widely used in biomarker discovery studies. In regards to the tissue where to 
look for biomarkers, human plasma was broadly exploited because potentially 
informative about almost any disease state and very easy to obtain with little discomfort 
for patients. Moreover, plasma seems to be suitable for proteomic analyses to be applied 
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in the clinical practice [9]. Nevertheless, the proteomic investigation of human plasma, 
especially by 2-DE, has proved to be challenging, because of the very complex nature of 
the sample and the presence of few highly-abundant proteins [10].  
Meta-analysis of proteomics data may represent a valuable tool to extract 
information from datasets present in the literature, thus increasing the sample size with 
respect to a single proteomics study [11]. In particular, meta-analysis of 2-DE data 
available in the literature has proved to have a great potential to retrieve valuable 
information related to Parkinson’s disease, which otherwise would remain hidden [12]. 
Plenty of information is available online in public domain databases. However, these 
datasets need to be filtered in order to sensibly and specifically find proteins that are 
associated to PD as biomarkers [13]. Here again, meta-analysis of 2-DE experiments 
present in the scientific literature or in pertinent datasets can help to identify 
biologically relevant biomarkers by filtering out proteins involved in generic processes 
(e.g., cell-cycle control, signal transduction, and stress responses) [14]. Eventually, the 
data obtained from the analysis of the literature should be further validated in an 
independent manner in a cohort large enough to ensure statistical significance.  
In this study, we developed a bioinformatic platform for the automatic analysis of 
proteomics literature data (Parkinson Informative System, ParIS, 
http://www.biodigitalvalley.com/researchprojects.html). We used a meta-analysis 
approach to filter literature data and identify a list of potential PD biomarkers, proposed 
by different authors and visible in 2-DE maps of human plasma. We further verified 
these markers in a cohort of 45 PD patients compared to 45 control subjects with 
neurological, non neurodegenerative disorders. Some of the markers were confirmed, 
while others did not reach statistical significance. Eventually, we built a predictive 
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model able to significantly stratify PD patients by the identification of all the spots 
whose level was significantly different in the two groups. 
 
2. Methods 
2.1. 2-DE gel database and proteomic meta-analysis 
In order to extract human plasma 2-DE images from the literature, we parsed PDF files 
of selected articles using the BFO Java library (http://bfo.com) as previously described 
[12]. Briefly, the 2-DE images extracted from proteomic papers were annotated for all 
the protein spots, according to identifications provided by the article authors, matching 
the symbols and labels on the gels to the information given in the tables or in the text of 
the paper. Spots were further associated to their pixel cartesian position and to pI and 
MW data. To get putative spot identification, we aligned the 22 literature-retrieved 2-
DE gels to the human plasma reference 2-DE map (PLASMA_HUMAN) from Expasy 
SWISS-2DPAGE (http://world-2dpage.expasy.org/swiss-2dpage/). To store all the 
retrieved gels and their annotations, a human plasma 2-DE gel database was built using 
a MySQL environment on a Red-Hat server.  
2.2. Subjects 
Ninety subjects were enrolled by the Department of Neurology at the Aosta Regional 
Hospital, after approval by the local Institutional Review Board. All patients signed an 
informed consent before being recruited for the present study, according to the 
Declaration of Helsinki. Every subject was associated to an alphanumeric code by the 
medical personnel involved in this study, to ensure that his/her identity was not apparent 
to investigators. Among the enrolled individuals, 45 subjects were idiopathic PD 
patients, varied in terms of age, age at onset, pharmacological treatment, with no 
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familiarity and no other co-occurring neurological disease. Beside personal details, for 
each subject affected by Parkinson’s disease we registered the presumptive onset year, 
the Hoehn & Yahr score and the dopaminergic therapy (Table 1). The 45 control 
subjects were recruited by the same Hospital Department among neurological patients 
not affected by neurodegeneration or multiple sclerosis. Gender and age distributions 
were similar in different groups (Table 1). Plasma samples were collected according to 
the protocol of the Parkinson’s progression markers initiative (http://www.ppmi-
info.org/wp-content/uploads/2012/03/PPMI-Biologics-Manual.pdf). Immediately after 
the blood collection the tubes were gently mixed and within 30 minutes the samples 
were centrifuged at 1500g at 4°C for 15 minutes. Plasma was collected into 1.5 ml 
aliquots and immediately stored at -80°C. 
2.3. Two-dimensional electrophoresis and image analysis 
Protein concentration in plasma samples was determined according to Bradford. An 
aliquot of 400 µg of proteins was mixed with 10 µl of a solution containing SDS (10% 
w/v) and DTT (2.3% w/v). The sample was heated to 95°C for 5 minutes and then 
diluted to 250 µl with a solution containing 7 M urea, 2 M thiourea, 4% CHAPS, 1% 
IPG buffer 4-7 (GE Healthcare, Uppsala, Sweden), 2% Amidosulfobetaine-14 (ASB-14; 
Sigma-Aldrich, St. Louis, MO, USA) and a trace of bromophenol blue. Total proteins 
were separated through 2-DE using 13 cm IPG DryStrips with a 4–7 pH gradient (GE 
Healthcare) followed by 12.5%T SDS-PAGE. The resulting maps were stained with 
Ru(II) tris(bathophenanthroline disulfonate) (Serva, Heidelberg, Germany). Images 
were acquired (12 bit grayscale) with the GelDoc-It Imaging System (UVP, Upland, CA, 
USA) and analyzed with Melanie 7.0 (GeneBio, Geneva, Switzerland); spots showing 
significant variation among subject groups (Wilcoxon test, p<0.05) and not recognized 
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by matching with the database created as described in paragraph 2.1 were excised from 
gels and the corresponding proteins identified by LC-MS/MS fragmentation.  
2.4. Statistical analysis  
Spot volumes were normalized by the total volume of a subset of spots common to all 
gels. Spots that were missing in more than 25% of gels were not taken into account. 
Missing spot values in less than 25% of gels were replaced by the mean value of the 
spot volume of the group or, if the mean was lower than the 98th percentile, by the 
minimum value observed in the group [15]. Relative volumes were analyzed by the 
non-parametric Wilcoxon test to find significant differences (p < 0.05) in patients with 
PD with respect to control subjects and in PD patients treated or not with dopamine 
agonists [16],[17].  
The Pearson linear correlation coefficient r was evaluated according to Eq. 1, where 
x is the independent variable (i.e., age, daily L-DOPA dose), y is the relative spot 
volume, x is the mean x value, y is the mean y value, xy is the x × y product, xy  is the 
product of x and y mean values.  
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


  (1) 
Predictive models for the classification of PD patients with respect to control 
subjects were built by linear discriminant analysis (LDA) of the spots identified as 
described above [16]. In this case, missing values were set to half of the minimum value 
observed in the gel. A likelihood score was assigned to each subject by linear 
combination of relative spot volumes according to Eq. 2. 
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ii i
VolcScore  PD
   (2) 
A simplified model was obtained by removing spots with lower discriminating 
weight (W), calculated according to Eq. 3,  
  PDiCOii VolVolcW ,, 
   (3) 
where ci is the LDA coefficient for spot i and 
  PDiCOi VolVol ,, 
 is the absolute 
separation of the mean values of spot i in control subjects (CO) and PD. Predictive 
models have been tested with the leave-one-out method and their performance 
quantified by measuring the area under the receiver operating characteristic (ROC) 
curve [16].  
Aggregative nesting of spots included in the predictive model was based on 
pairwise Pearson correlation (Eq. 1), where x and y are relative spot volumes. 
The minimum number of subjects to be included in validation studies was 
calculated according to Eq. 4, 
   
 
2
22
2.2
2
11





 



PDCO
PDCO
PDPDCOCO
NN
NN
n


  (4) 
where σCO and σPD are standard deviations of relative spot volumes in CO and PD 
groups, NCO and NPD are numbers of subjects in the groups, and μCO and μPD are mean 
values of relative spot volumes in the groups [16]. 
All procedures for data analysis and graphics were written in R, an open-source 
environment for statistical computing [18] and are available at 
http://dx.doi.org/10.1038/protex.2013.001.  
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2.5. In-gel digestion, mass spectrometry and protein identification  
Spots were manually excised and destained (50% ethanol), dehydrated with acetonitrile 
(Sigma-Aldrich) (2 × 100 µl, 20 min) and then dried at 37°C by vacuum centrifugation. 
Protein spots were trypsin digested as already described [19].  
Protein identification by LC-MS/MS was performed by Primm (Milan, Italy). 
Peptides from each sample were separated by HPLC 1100 online-coupled with a 
LC/MSD XCT Ultra Ion Trap (Agilent Technologies, Santa Clara, CA, USA), equipped 
with a HPLC 1100 and a chip cube (Agilent Technologies). Protein identification was 
performed by searching the National Center for Biotechnology Information non-
redundant database using the Mascot MS/MS Ion Search program 
(http://www.matrixscience.com) with the built-in decoy option. The following 
parameters were set: ESI TRAP instrument, specific trypsin digestion, up to one missed 
cleavage, complete carbamidomethylation of cysteines, partial oxidation of methionines, 
partial protein N-terminal acetylation, peptide mass tolerance ± 600 ppm, fragment 
mass tolerance ± 0.6 Da, 2+ to 3+ peptide charge, species restriction to human. All 
identified proteins had a MOWSE score corresponding to a statistically significant (p < 
0.05) confident identification. At least 2 different peptides had to be assigned. 
 
3. Results 
3.1 Meta-analysis reveals nine candidate PD biomarkers  
First of all, as described in the methods section we have populated a database with 22 2-
DE gel images of whole human plasma, extracted from proteomics papers or from the 
Swiss 2D page database (http://world-2dpage.expasy.org). The gel spots were annotated 
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as described in paragraph 2.1. Within the selected 22 images, we have assigned 927 
different spots corresponding to a total of 188 independent proteins. 
We filtered these proteins in order to consider only those having at least two 
citations in papers related to PD. To this aim, we used ProteinQuest 
(http://www.proteinquest.com), a web-based platform for the mining of Medline papers, 
which allows the identification of the co-occurrence of biological concepts (e.g., 
proteins, disease names, drugs). In particular, we used ProteinQuest to analyze the co-
occurrence between PD-related terminology and the 188 proteins annotated in our 2-DE 
gel database. As a result, 84 of these proteins occurred in at least two papers related to 
PD. Among these proteins, we selected only proteins that were already defined as 
potential PD biomarkers (e.g., by ignoring proteins related to the pathogenesis) and 
were detectable in 2-DE plasma gels (thus excluding proteins with low abundance). In 
this way, we identified 9 different proteins (haptoglobin (HP), transthyretin (TTR), 
apolipoprotein A-1 (APOA1), serum amyloid P component (SAP), apolipoprotein E 
(APOE), complement factor H (CFH), fibrinogen γ (FGG), thrombin (F2) and 
complement c3 (C3)) that satisfy all the requirements, i.e., to be a protein visible on a 
plasma 2-DE gel and at the same time to be known as a potential biomarker of PD. The 
nine potential biomarker proteins, split into 32 spots, were identified as suitable source 
for a diagnostic pattern and were considered for the subsequent analysis; the increase or 
decrease of protein concentration as expected from the analyzed literature is reported in 
Supplementary Table 1. 
3.2 Two-dimensional electrophoresis profiling of plasma proteins  
To perform the biomarker validation analysis, we obtained plasma protein expression 
profiles from the enrolled groups by 2-DE. First, we performed technical replicates for 
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14 PD patients and 17 control subjects in order to evaluate the linear correlation of spot 
volumes as a reproducibility benchmark of the maps. Most of the gel pairs display linear 
correlation of spot volumes with Pearson correlation coefficient greater than 0.8 (Fig. 
1A). Moreover, we calculated the intra-group standard deviation of spot volumes to 
verify if they were normally or log-normally distributed. As commonly observed in 
biological variables, standard deviations of spot volumes after logarithmic 
transformation were constant in both groups (Fig. 1B). For this reason, we decided to 
rely on the non-parametric Wilcoxon test [16]. Moreover, we compared pairs of 2-DE 
gels from different subjects by Pearson linear correlation and analyzed the distribution 
of fitting residuals to assess the correctness of a pairwise comparison. Supplementary 
Fig. 1 shows the studentized residuals against ranked magnitudes (QQ) plots [18]. On 
this basis, a direct proportionality between gels from different subjects may be assumed.  
Once tested the quality of 2-DE maps, we screened the profiles to identify proteins 
or protein modifications whose changes were linked to confounding factors such as 
therapy and age. Spots showing linear Pearson correlation with age (evaluated in control 
subjects only) or daily L-DOPA dose, or showing significant differences between 
patients treated or not with dopamine agonists (Wilcoxon test, p<0.05) were excluded 
from the further analysis. By comparing 2-DE maps from the 45 PD patients to the 45 
control subjects, we selected 26 protein spots showing significantly different levels in 
the two groups (Wilcoxon test, p<0.05) (Fig. 2 and Table 2). For spots accurately 
matching with the 2-DE annotated map of human plasma obtained as described in 
paragraph 2.1 (no. 22, 23, 24, 25, 34, 38, 43, 44, 46, 61, 62, 92, 97, 113, 117, 132, 141, 
147, 150 and 151), the protein identity was assumed to be unambiguous. Other spots (no. 
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26, 41, 45, 66, 89 and 105) were identified by LC-MS/MS (see Table 3 and 
Supplementary Table 2 for details on protein identification by mass spectrometry).  
3.3 Validation of candidate biomarkers 
First of all, we verified the presence of the nine candidate biomarkers identified as 
described in paragraph 3.1 among the proteins that showed significant changes in our 
experimental data. Haptoglobin, transthyretin, apolipoprotein A-1, apolipoprotein E, 
complement factor H and a complement c3 fragment were confirmed to be markers of 
the disease. Indeed, we observed altered levels in spot no. 22-26, 38, 43, 92, 97, 113, 
117, 132, 141, 151 (for spot-protein correspondence see Table 2).  
On the contrary, serum amyloid P component, fibrinogen γ and thrombin were 
excluded from the diagnostic pattern because not confirmed by our experimental data. 
Interestingly, FGG was excluded because the level of spots corresponding to this 
protein correlated with L-DOPA daily dose and age.  
Eventually, dealing with a large cohort of subjects, we observed significant level 
changes in spots that were not included in the results of the meta-analysis procedure 
(Spots no. 34, 41, 44, 45, 46, 61, 62, 66, 105, 147 and 150), thus allowing us to enrich 
the list of biomarker candidates found in plasma by 2-DE (for spot-protein 
correspondence see Table 2). 
3.4 Linear discriminant analysis of selected spot levels  
We analyzed all spots (n = 25) showing significantly different levels in PD patients by 
LDA, so to select the spots with the higher weight. The 10 spots showing the worst 
contribution (weight < 0.07) were discarded. The remaining 15 spots were clustered by 
aggregative nesting to detect the extent of correlation among spots (Fig. 3A). These 
spots were analyzed again by LDA. Likelihood scores (PD Score, obtained as a linear 
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combination of relative spot volumes) were significantly different in PD patients with 
respect to control subjects (Wilcoxon test, p < 10
-16
) (Fig. 3B). To effectively test the 
performance of the model, each subject was iteratively excluded from the training set 
and predicted on the basis of the other subjects. The "leave-one-out" cross-validation 
procedure of the model allowed us to obtain 83% sensitivity and 82% specificity. 
Predictions obtained so far were used to build a ROC curve with an area under curve of 
0.886 (Fig. 3C).  
To test the power of our analysis we evaluated the intra-group variance and the 
difference of mean values for each spot listed in Table 2. The minimum number of 
subjects required for a significant verification is always lower than 45 with the only 
exception of spots 38, 44 and 117 (Supplementary Table 3).  
 
4. Discussion 
Here we show a method for the validation of candidate biomarkers as reported by the 
literature. Focusing on plasma biomarker discovery studies for Parkinson's disease 
diagnosis, we identified a subset of proteins that at the same time have been associated 
to Parkinson's disease and have been detected by 2-DE. Actually, the experimental 
result of 2-DE is a digital image that can be retrieved in an automatic way. The creation 
of a human plasma 2-DE gels database and the analysis of PD biomarkers papers in 
Medline with the application of suitable filters allowed us to focus on a reduced set of 
proteins to be further validated as PD biomarkers.  
The choice of plasma as the source of biomarkers has been imposed by the high 
number of papers where biomarker discovery was performed in this biofluid. However, 
plasma may represent a challenging matrix for proteomics studies, especially for those 
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based on 2-DE [10]. Indeed, the use of 2-DE as the separating step in differential 
proteomics is controversial, since the technique is usually considered to show an 
intrinsically low reproducibility and low sensitivity. Moreover, in the case of plasma 2-
DE separation, the detection of biomarkers is limited to the most abundant proteins [7]. 
Nevertheless, 2-DE images represent a direct display of protein expression in a tissue or 
biofluid.  
In order to evaluate the effective suitability of candidate biomarkers by 2-DE, we 
first measured technical reproducibility in our set of 121 gel images. Noticeably, we 
observed a very low dispersion of Pearson correlation coefficients for 31 pairs of 
technical replicates, with values r > 0.8. Moreover, the normal distribution of linear 
fitting residuals when 2-DE gels from different subjects are compared ensures that a 
pairwise gel comparison is methodologically correct (Supplementary Fig. 1). Eventually, 
our experimental design included a group of non-healthy control subjects in order to 
eliminate false candidate biomarkers linked to a general state of inflammation present in 
PD patients. Indeed, different pieces of evidence suggest a possible implication of 
inflammation in the degeneration of dopaminergic neurons [20]. 
Despite the precautions to avoid possible common biases of biomarkers discovery 
studies, our approach verified six out of nine candidate biomarkers, namely haptoglobin, 
transthyretin, apolipoprotein A-1, apolipoprotein E, complement factor H and 
complement c3. In particular, HP and CFH showed the highest significance.  
HP is an acute phase protein synthesized by liver cells, which has been widely 
proposed as a PD biomarker [21],[22]. HP probably plays a modulatory and protective 
role on autoimmune inflammation of the CNS [23] and on the integrity of the nigro-
striatal dopaminergic system [24]. Therefore, its altered levels could mirror the 
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neurodegenerative process at the central level. Notwithstanding this, a single isoform of 
HP was excluded from the panel because of its correlation with the assumption of 
dopamine agonists. The advantage of 2-DE, in this case, is the possibility to analyze the 
different forms of the same protein separately. CFH is a cofactor in the inactivation of 
C3b by factor I and also increases the rate of dissociation of the C3bBb complex (C3 
convertase) and the (C3b)NBB complex (C5 convertase) in the alternative complement 
pathway. Our results support the hypotheses of a dysregulation of the complement 
pathways in neurodegenerative disorders and in PD in particular [7] and are in 
agreement with a significant reduction in factor H levels observed in the CSF of PD 
patients [25]. A single fragment of C3 was found to change in our cohort, but we cannot 
exclude that other fragments beyond our limit of detection are effectively changing. In 
any case, the power analysis revealed that this spot is characterized by a high variability 
and that the number of subjects to be analyzed should be higher. Also TTR would 
require a higher number of subjects to be considered a real PD biomarker.  
On the other hand, we were not able to confirm the validity of thrombin (F2), 
gamma fibrinogen (FGG) and serum amyloid P component (SAP). Thrombin exerts 
physiological and pathological functions in the central nervous system, and it has been 
documented that the level of thrombin increases in human brain of patients with 
Parkinson's disease [26],[27]. Nevertheless, the differences in concentration may not be 
detected at the peripheral level. Additionally, higher F2 levels have been associated to 
ischemic injury [28], a finding that could reduce the significance of this candidate 
biomarker when control subjects include stroke patients as it is our case. SAP was not 
significantly different between patients and control subjects, probably because PD 
patients were compared with neurological control subjects, who might have altered 
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levels of acute phase proteins. Moreover, even if FGG was correlated to PD, we 
excluded it from the panel because of the correlation of its levels with the therapy 
assumed by PD patients. In verification studies, it is particularly important to eliminate 
confounding effects such as the pharmacological treatment, that intrinsically 
discriminate between patients and control subjects [17]. 
Furthermore, the experimental validation procedure allowed us to identify a set of 
additional candidate biomarkers that were not present in the list of proteins to be 
validated in the present study. Some of them have been already associated to PD, 
however they were not identified by the automated literature search because they did 
not fulfill the stringency parameters imposed in the analysis process. For instance, 
apolipoprotein A-IV has been proposed as a plasma PD biomarker only once [22]. 
Therefore, it was filtered out during the automated analysis of literature.  
In other cases, we observed a significant variation in proteins whose change in 
association with PD was not reported previously or is controversial. For instance, we 
observed that α2-macroglobulin level was lower in plasma of PD patients with respect 
to neurological, non-neurodegenerative control subjects. This protein has been 
originally proposed as a PD marker [29], but other studies contradict the original 
hypothesis [30]. As a matter of fact, like many other inflammatory markers, α2-
macroglobulin displays constant levels in PD patients with different motor and 
cognitive impairment [31]. This finding highlights again the importance of the choice of 
the appropriate control group.  
Eventually, a linear discriminant analysis was applied to identify the set of 15 spots 
that performed at best in discriminating PD patients from control subjects. A 
hierarchical clustering of these spots showed a major contribution of HP isoforms, 
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segregated in a single cluster of the dendrogram. The only other cluster contains other 
proteins, with a main contribution of apolipoproteins. By considering proteins identified 
both by the literature analysis and the experimental assessment, it was possible to build 
a PD predictive model. The ROC curve obtained by the leave-one-out cross validation 
demonstrates a quite good predictive power, with AUC= 0.886. Remarkably, a pattern 
recognition tool would allow to calculate a PD score from the plasma 2-DE map of a 
subject, independently from proteins identity. 
 
5. Conclusions 
The present study shows a possible pipeline to validate candidate PD biomarkers. 
Starting from a broad automated analysis of the literature, we selected few proposed 
biomarkers in plasma and verified them in a cohort of 90 subjects. Some of the 
candidates, that arose from the literature analysis, were confirmed. At the same time, we 
identified other proteins whose level was different between PD patients and control 
subjects. Putting all the results together, we performed a LDA and assigned a weight to 
each protein. In this way, we selected the 15 most relevant contributors to a PD 
predictive model. Taken altogether, these data suggest that an automated analysis of 
literature data provides a useful tool to biomarkers validation studies. 
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Table 1: Summary of enrolled subjects 
 Controls (n = 45) PD (n = 45) 
Anamnestics   
Age ± SD (years) 69.1 ± 8.7 70.3 ± 7.7 
Gender (males)  23 (51%) 26 (58%) 
PD duration ± SD (years)  7.3 ± 4.3 
Medications   
Unmedicated  0 
L-DOPA  5 
DA agonists  12 
L-DOPA + DA agonists   28 
Hoehn and Yahr stage   
1  14 (31%) 
2  14 (31%) 
3  13 (29%) 
4  3 (7%) 
5  1 (2%) 
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Table 2: Identity of protein spots  
Match ID a Protein name Gene Symbol b pI c MW c p Value d Fold of Change e 
22 Haptoglobin Beta Chain HP 5.08 41412 7.510-05 0.654 
23 Haptoglobin Beta Chain HP 4.97 42114 5.910-03 0.715 
24 Haptoglobin Beta Chain HP 4.81 44464 2.810-07 0.630 
25 Haptoglobin Beta Chain HP 5.21 41329 3.910-04 0.715 
26 Serum albumin ALB 5.43 41412 1.410-02 1.162 
34 Ig mu chain C region IGHM 6.05 48501 1.910-02 1.145 
38 Transthyretin TTR 5.52 13800 1.710-02 1.187 
41 Tetranectin CLEC3B 5.38 19391 1.610-04 1.316 
43 Haptoglobin Alpha Chain HP 6.07 16882 5.610-04 0.697 
44 Alpha-1-microglobulin AMBP 5.07 30920 4.010-02 0.871 
45 Serum albumin ALB 6.06 58451 2.410-02 1.223 
46 Fibrinogen beta chain FGB 6.41 55252 4.410-02 0.869 
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61 Hemopexin HPX 5.43 74551 4.710-02 0.848 
62 Hemopexin HPX 5.53 73703 4.510-02 0.863 
66 Complement C4-A or B C4 5.9 41412 1.110-02 0.783 
92 Haptoglobin Beta Chain HP 5.38 38749 6.310-04 0.772 
97 Complement factor H CFH 5.68 99064 5.010-04 1.402 
105 Alpha-2-macroglobulin  A2M 5.44 143064 3.310-02 0.750 
113 Apolipoprotein A-I APOA1 5.22 23000 3.110-03 1.119 
117 Complement C3 C3 4.84 40915 2.010-02 0,911 
132 Haptoglobin Beta Chain HP 4.88 43156 4.510-04 0.672 
141 Apolipoprotein E APOE 5.53 33925 3.910-03 0.699 
147 Apolipoprotein A-IV APOA4 5.16 43627 8.710-04 1.306 
150 Immunoglobulin light chain IGHL 7.03 26973 3.310-02 1,200 
151 Haptoglobin Alpha Chain HP 5.4 16882 2.310-04 0.766 
 
a
  Spots are numbered according to map detection and matching. 
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b  
Official symbol from http://www.ncbi.nlm.nih.gov/gene. Symbols in bold refer to gene products retrieved by the automated literature 
analysis.  
c  Predicted pI and Mr according to protein sequence as computed by the Compute pI/Mw tool (http://web.expasy.org/compute_pi/). 
d
  Based on Wilcoxon test. 
e
  Expressed as PD/control spot volume ratios. 
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Table 3 Mass Spectrometry identification of selected spots 
Match ID  Protein name Uniprot ID a Mr. (kDa)  theor b pI theor b 
Mr. (kDa)  exp 
c 
pI exp c 
No. of 
peptides 
identified 
MOWSE 
score d 
Sequence 
Coverage 
(%) 
26 Serum albumin P02768 71 5.92 41 5.43 11 965 35% 
41 Tetranectin P05452 23 5.52 20 5.3 2 80 16% 
45 Serum albumin P02768 68 5.67 59 6.06 12 766 53% 
66 Complement C4 P0C0L4 48 5.78 40 6.0-6.5 4 175 20%  
105 
Alpha-2-
macroglobulin 
P01023 162 5.95 120  5.5 19 1075 35% 
  
a
 http://www.uniprot.org. 
b
 Predicted pI and Mr according to protein sequence as computed by Mascot search results  (http://www.matrixscience.com). 
c
 See [12]. 
d
 http://www.matrixscience.com. 
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Caption to the Figures 
 
Figure 1:  Statistical assessment of the quality of 2-DE maps. Spot volumes have 
linear correlation coefficients greater than 0.8 when technical replicates of 
the same specimen are compared, as indicated by the box-and-whiskers 
plot (A). Spot volumes show log-normal distributions both in control 
subjects (filled circles) and in PD patients (open circles) (B). 
Figure 2: Representative 2-DE map of human plasma. Spots showing significantly 
different abundance are contoured in green. Gene symbols are reported 
only for spots belonging to the nine candidates list. HPα and HPβ refers to 
the α and β chains of haptoglobin. 
Figure 3:  Discriminant analysis of the 15 spots that best discriminate PD patients. 
Hierarchical clustering of spot intensities shows two outgroups. One of 
them groups together all HP isoforms, while the other includes all the 
other spots and is enriched in apolipoproteins (A). Panels B and C report 
prediction results by the "leave-one-out" cross-validation procedure in 
terms of PD likelihood score distribution in the two groups (B) and 
classification performance, represented by the ROC curve (C). 
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Highlights 
 
 An automated literature analysis procedure retrieved plasma PD biomarkers.  
 9 different proteins were identified as a potential PD diagnostic pattern. 
 We verified some candidate biomarkers in 2-DE plasma maps of 90 subjects.  
 
 
